Centessa Pharmaceuticals PLC ADR

NASDAQ CNTA

Data sourced from

and

Download Data

Centessa Pharmaceuticals PLC ADR Sales to Operating Cash Flow Ratio 5 year CAGR for the year ending December 31, 2023

Centessa Pharmaceuticals PLC ADR Sales to Operating Cash Flow Ratio 5 year CAGR is NA for the year ending December 31, 2023. Sales to operating cash flow ratio measures the revenue generated by a company relative to its operating cash flow. It is calculated by dividing the revenue by the operating cash flow. This ratio provides insights into the efficiency of revenue generation compared to the company's operating cash flow. A higher sales to operating cash flow ratio suggests better revenue generation efficiency. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Centessa Pharmaceuticals PLC ADR Sales to Operating Cash Flow Ratio for the year ending December 31, 2022 was -0.00.
Centessa Pharmaceuticals PLC ADR Sales to Operating Cash Flow Ratio for the year ending December 31, 2020 was -0.00, a 0.00% change year over year.
Centessa Pharmaceuticals PLC ADR Sales to Operating Cash Flow Ratio for the year ending December 31, 2019 was -0.00.

NASDAQ: CNTA

Centessa Pharmaceuticals PLC ADR

CEO	Dr. Saurabh Saha M.D., Ph.D.
IPO Date	May 28, 2021
Location	United Kingdom
Headquarters	1 Ashley Road, Altrincham, United Kingdom, WA14 2DT
Employees	77
Sector	Healthcare
Industry	Biotechnology

Description

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Key trends